肺癌治疗的分子靶位及其相关药物的研究进展被引量：1

Progress in molecular targets and associated drugs for lung cancer treatment

导出

摘要肺癌的靶向治疗是现在肺癌治疗研究的热点。近年来,新的治疗分子靶位不断地被发现,据此开发的新药有些已进入临床实验或临床应用。本文对近年出现的一些肺癌治疗的分子靶位及其相关药物作一综述。 Targeting treatment for lung cancer is ahot point now. In the latest years,new molecular target and associated drugs have been tested,even used for lung cancer treatment have been being discovered continuously. Some of them clinically. Here we review molecular targets and associated drugs for lung cancer treatment in recent years.

作者张鼎陈小东

机构地区复旦大学附属华山医院呼吸内科

出处《国际呼吸杂志》 2007年第10期750-753,共4页 International Journal of Respiration

关键词肺癌治疗分子靶位 Lung cancer Targeting treatment

分类号 R734 [医药卫生—肿瘤]

引文网络
相关文献

参考文献29

1Parkin DM, Bray FI, Devesea SS. Cancer burden in the year 2000 : the global picture. Eur J Cancer, 2,001,37(Suppl) :4-66.
2Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell, 2003, 4: 431-436.
3Dubinett SM, Sharma S, Huang M, et al. Cyclooxygenase-2 in lung cancer. Prog Exp Tumor Res, 2003,37 :138-162.
4Krysan K, Dohadwala K, Luo J, et al. Cyclooxygenase-2 dependent expression of suavivin in non-small cell lang cancer. Chest, 2004,125 (Suppl) : 140S.
5Pold M, Zhu LX, Sharma S, et al. Cyclooxygenase-2 dependent expression of angioenie CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interlueukin-8/CXCL8 in human non-small cell lung cancer. Cancer Res, 2004,64 : 1853-1860.
6Castelao JE, Bart RD 3rd, Diperna CA, et al. Lung cancer and cyclooxygenase-2. Ann Thorac Surg,2003,76:1327-1335.
7Kobayashi H, Uetake H, Higuchi T, et al. JTE-522, a selective COX-2 inhibitor, inhibits growth of pulmonary metastases of colorectal cancer in rats. BMC Cancer, 2005,5 : 26.
8Klenke FM, Gebhard MM, Ewerbeck V, et al. The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors:an intravital microscopy study in mice. BMC Cancer, 2006,6 : 9.
9Cohen MH,Williams GA, Sridhara R, et al. United states food and drug administration drug approval summary:Gefitinib (ZD1839 ; Iressa) tablets. Clin Cancer Res, 2004,10 : 1212-1218.
10Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol, 2003,21 : 2237-2246.